Movement Alert｜Novartis AG Falls 4.04% in Pre-Market Trading, Zolgensma Tumor Cases Renew Safety Concerns

Market Focus11-09

On November 9, Novartis AG fell 4.04% in Pre-Market Trading, trading at $163.6255 per share, with turnover of $415,800.

The move aligned with renewed investor concern over the safety profile of Zolgensma after the company confirmed nine post-marketing tumor reports, including two cases with evidence that vector DNA had integrated into patients' genomes.

The latest safety development appears to be the clearest near-term catalyst for the stock weakness. Earlier positives, including Novartis AG's raised full-year core operating income outlook after third-quarter results, had largely been absorbed by the market. Separately, the company also recently disclosed it was largely abandoning development of pelacarsen after a large phase 3 cardiovascular study failed to reduce heart attack, stroke, or cardiovascular death despite lowering Lp(a) by 78%, adding to broader pipeline execution concerns.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment